David Lebowitz
Stock Analyst at Citigroup
(4.30)
# 370
Out of 5,152 analysts
119
Total ratings
59.77%
Success rate
13.74%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $74.44 | +12.84% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $60.54 | +38.75% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $29.27 | +63.99% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $13.05 | +53.26% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $237.12 | +22.30% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $95.26 | +8.13% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $31.56 | +20.41% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $37.30 | -41.02% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $64.75 | +3.47% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $41.04 | +36.45% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $13.35 | -25.09% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.30 | +15.83% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $62.30 | -27.77% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $88.56 | -23.22% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $435.29 | -12.24% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $60.05 | +59.87% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $5.15 | +133.01% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $318.73 | -48.55% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $23.66 | +64.84% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $21.96 | -4.37% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $9.00 | +4,400.00% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.54 | +295.48% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $74.44
Upside: +12.84%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $60.54
Upside: +38.75%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $29.27
Upside: +63.99%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $13.05
Upside: +53.26%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $237.12
Upside: +22.30%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $95.26
Upside: +8.13%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $31.56
Upside: +20.41%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $37.30
Upside: -41.02%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $64.75
Upside: +3.47%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $41.04
Upside: +36.45%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $13.35
Upside: -25.09%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.30
Upside: +15.83%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $62.30
Upside: -27.77%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $88.56
Upside: -23.22%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $435.29
Upside: -12.24%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $60.05
Upside: +59.87%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $5.15
Upside: +133.01%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $318.73
Upside: -48.55%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $23.66
Upside: +64.84%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $21.96
Upside: -4.37%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $9.00
Upside: +4,400.00%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.54
Upside: +295.48%